文献速递哮喘慢阻肺

哮喘-慢阻肺重叠:关键问题何在?

Asthma-COPD Overlap: What Are the Important Questions?
PubMed 文献 · Chest · 2021-10-06

哮喘-慢阻肺重叠(ACO)是一种异质性疾病,表现为持续性气流受限并兼具哮喘与慢阻肺临床特征。其患病率因诊断定义不同在普通人群中为0.9%至11.1%,患者症状负担、生活质量及急性加重均更重。ACO患者常被排除在治疗试验之外,亟需生物标志物与循证治疗研究。

要点

  • ACO无单一共识定义,主要标准包括支气管舒张可逆性或高反应性、医生诊断哮喘及≥10包年吸烟史。
  • ACO患者较单纯哮喘或慢阻肺症状负担更重、生活质量更差、急性加重更频繁且严重。
  • ACO治疗证据有限,一线吸入治疗外的高级治疗按表型外推自哮喘和慢阻肺数据。

核心结论

  • ACO是异质性疾病,定义不统一导致患病率差异大,患者负担重且缺乏循证治疗推荐。

研究设计与样本

  • 本文为综述,未报告系统检索范围与样本量。

主要发现

  • 普通人群中ACO患病率范围为0.9%至11.1%,取决于所用诊断定义。
  • ACO患者较哮喘或慢阻肺患者症状负担更大、生活质量更差、呼吸急性加重更频繁且严重。
  • 早期因素如儿童期起病哮喘与吸烟可能交互增加成年后气流阻塞风险。
  • 生物标志物与遗传分析提示ACO为异质性疾病但具有可定义特征。

关键数值与推荐

  • 常见主要标准包括强支气管舒张可逆性或支气管高反应性、医生诊断哮喘及≥10包年吸烟史。

临床怎么用

  • ACO高级治疗按疾病表型选择,基于从哮喘和慢阻肺外推的数据。
  • 一线吸入治疗外缺乏强循证推荐,需关注生物标志物研究进展。

局限性

  • ACO人群历史上被排除在治疗试验之外,导致循证推荐缺乏。
  • 无单一共识定义,患病率估计受诊断标准影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asthma-COPD overlap (ACO) is a heterogeneous condition that describes patients who show persistent airflow limitation with clinical features that support both asthma and COPD. Although no single consensus definition exists to diagnose this entity, common major criteria include a strong bronchodilator reversibility or bronchial hyperreactivity, a physician diagnosis of asthma, and a ≥ 10-pack-year cigarette smoking history. The prevalence of ACO ranges from 0.9% to 11.1% in the general population, depending on the diagnostic definition used. Notably, patients with ACO experience greater symptom burden, worse quality of life, and more frequent and severe respiratory exacerbations than those with asthma or COPD. The underlying pathophysiologic features of ACO have been debated. Although emerging evidence supports the role of environmental and inhalational exposures in its pathogenesis among patients with a pre-existing airway disease, biomarker profiling and genetic analyses suggest that ACO may be a heterogeneous condition, but with definable characteristics. Early-life factors including childhood-onset asthma and cigarette smoking may interact to increase the risk of airflow obstruction later in life. For treatment options, the population with ACO historically has been excluded from therapeutic trials; therefore strong, evidence-based recommendations are lacking beyond first-line inhaler therapies. Advanced therapies in patients with ACO are selected according to disease phenotypes and are based on extrapolated data from asthma and COPD. Research focused on defining biomarkers and evidence-based treatment options for ACO is needed urgently.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Leung C, Sin DD. Asthma-COPD Overlap: What Are the Important Questions? Chest. 2021. PMID: 34626594. doi:10.1016/j.chest.2021.09.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。